May 2021

Linnea Cannabis-based products submitted for EFSA Novel Food approval

We truly believe in the potential of Cannabis in the dietary and nutritional industry, and we invest daily to improve and expand the range of products we offer.

Linnea is pleased to announce that it has submitted its Cannabis-based products for Novel Food approval with the EFSA (European Food Safety Authority).

You can learn about novel food and the application process on the EFSA website: https://bit.ly/2QaxgsA.

For more on the EU Commission, please visit: https://bit.ly/3hhDnX7.

Botanical Ingredients

From selected botanical ingredients to innovative natural solutions

All Linnea ingredients are manufactured in our Swiss GMP facility for use as pharmaceutical, cosmetic or dietary supplement products.

Linnea ingredients are active pharmaceutical ingredients, purified ingredients and herbal extracts. Two recently developed technologies, NeoSol^TM and NioSkin^TM, improve the solubility and skin permeability of active compounds and herbal extracts.

Cannabis Therapeutic Solutions

Phytocannabinoids for pharmaceutical purposes

Every day, we develop and produce the finest cannabis and CBD extracts complying with the highest industry standards.

There are a large number of ongoing clinical and preclinical studies focusing on CANNABIS and CANNABINOIDS. CANNABIS and its derivatives has a multi-levels role in the organism, indicating the potential extent of a complex therapeutic scenario and representing an exciting target for disease management and health promotion.

Natural Ingredients

We have developed an advanced system for dermal delivery based on the perfect balance between science and nature: NioSkin^TM

The NioSkin^TM line is created with Linnea’s natural active ingredients.

For further information visit: Nioskin.ch